Menu Close

Ibrutinib/CAR T Cell Combo Active in CLL

Concurrent treatment with ibrutinib (Imbruvica) and the CD19-targeted chimeric antigen receptor (CAR) T-cell therapy JCAR014 was well tolerated and led to an overall response rate (ORR) of 83% in patients with relapsed or refractory chronic lymphocytic … (본문 전체 12/2/2018 11:51 AM)

Ibrutinib/CAR T Cell Combo Active in CLL

Concurrent treatment with ibrutinib (Imbruvica) and the CD19-targeted chimeric antigen receptor (CAR) T-cell therapy JCAR014 was well tolerated and led to an overall response rate (ORR) of 83% in patients with relapsed or refractory chronic lymphocytic … (본문 전체 12/2/2018 11:50 AM)